Fulcrum Therapeutics, Inc.

NASDAQ:FULC

Biotechnology

Healthcare
$3.72 +1.71%

+$0.06 today

Market cap
$284.14M
Beta
2.92
P/E (TTM)
-3.6
EPS (TTM)
-$1.00
52W Low $2.83High $15.74

Volume 0.63M

Average 1.78M

FULC Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Fulcrum Therapeutics, Inc.NASDAQ: FULC

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Context

  • Gross margin widened in 1 of the last 2 fiscal years.
  • FY2024 was the highest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2024
20.8%
Year-over-year change
+2480.5pp

Gross Margin vs competitors

How FULC compares with its peers on the latest reported figures

FULC Competitors Peer median
Gross Margin for FULC and competitors
Company Period LTM level YoY 3-year change
OCGNOcugen, Inc.LTM Mar 2026100.0% +0.0 pp-54.1 pp
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 202699.1% +83.0 pp+37780.7 pp
LCTXLineage Cell Therapeutics, Inc.LTM Mar 202698.0% +0.8 pp-0.9 pp
ADCTADC Therapeutics S.A.LTM Mar 202690.7% -2.0 pp-7.9 pp
BCYCBicycle Therapeutics plcLTM Mar 2026-11.9% +506.2 pp+0.0 pp
OMEROmeros CorporationLTM Mar 2026-12.4% ——
FULCFulcrum Therapeutics, Inc.FY2025— ——
NGNENeurogene Inc.FY2025— ——
CMPXCompass Therapeutics, Inc.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding FULC) 94.3%+0.8 pp-0.9 pp

Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue19.16M6.34M2.81M80M0
Cost of Revenue69.7M76.78M71.8M63.39M1.39M
Gross Profit(50.54M)(70.44M)(69M)16.61M(1.39M)
Gross Margin-263.7%-1110.7%-2459.8%20.8%—
Research & Development69.7M76.78M71.8M63.39M56.1M
Selling, General & Admin30.52M41.69M41.67M36.45M28.67M
Operating Expenses30.52M42.12M41.67M38.51M83.38M
Depreciation & Amortization2.52M2.41M2.17M1.59M1.39M
EBITDA(78.33M)(109.72M)(95.16M)(18.24M)(73.49M)
EBITDA Margin-408.8%-1730.1%-3392.6%-22.8%—
Operating Income(81.05M)(112.56M)(110.66M)(21.9M)(84.77M)
Operating Margin-423.0%-1774.9%-3945.2%-27.4%—
Interest Income207K0000
Interest Expense00000
Other Income / Expenses207K2.69M13.33M12.17M9.89M
Income Before Tax(80.85M)(109.87M)(97.34M)(9.73M)(74.88M)
Pre-Tax Margin-421.9%-1732.4%-3470.1%-12.2%—
Income Tax Expense00000
Net Income(80.85M)(109.87M)(97.34M)(9.73M)(74.88M)
Net Margin-421.9%-1732.4%-3470.1%-12.2%—
EPS (Basic)(2.22)(2.35)(1.59)(0.16)(1.18)
EPS (Diluted)(2.22)(2.35)(1.59)(0.16)(1.18)
Weighted Avg Shares35.36M44.99M61.31M61.98M63.36M
Weighted Avg Shares (Diluted)35.36M44.99M61.31M61.98M63.36M

Fulcrum Therapeutics, Inc.

NASDAQ:FULC

Intrinsic Alpha fair value

Locked

Current Price

$3.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.